| 1 |
Verma HK, Bhaskar L. SARS-CoV-2 infection in people with pre-existing liver disease: Further research is warranted. World J Gastroenterol 2021; 27(45): 7855-7858 [PMID: 34963747 DOI: 10.3748/wjg.v27.i45.7855] [Reference Citation Analysis]
|
| 2 |
Husain A. A novel approach to minimize the false negative COVID-19 diagnosis by inclusion of specific cell markers and multiple sample collection. MethodsX 2021;8:101270. [PMID: 33614422 DOI: 10.1016/j.mex.2021.101270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
El-Shahat RA, El-Demerdash RS, El Sherbini ES, Saad EA. HCl-induced acute lung injury: a study of the curative role of mesenchymal stem/stromal cells and cobalt protoporphyrin. J Genet Eng Biotechnol 2021;19:41. [PMID: 33721136 DOI: 10.1186/s43141-021-00139-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 4 |
Mena-Vázquez N, Manrique Arija S, Rojas-Giménez M, Raya-Álvarez E, Velloso-Feijoó ML, López-Medina C, Ramos-Giraldez C, Godoy-Navarrete FJ, Redondo-Rodríguez R, Cabezas-Lucena AM, Morales-Águila M, Romero-Barco CM, Fernández-Nebro A. Hospitalization and mortality from COVID-19 of patients with rheumatic inflammatory diseases in Andalusia. Reumatol Clin (Engl Ed) 2021:S2173-5743(21)00162-3. [PMID: 34538612 DOI: 10.1016/j.reumae.2021.02.006] [Reference Citation Analysis]
|
| 5 |
Ulayya AH, Mubarok AZ, Widodo W, Widjanarko SB, Marlita M. The Importance of Natural ACE2 Inhibitor: Potency of Porang (Amorphophallus muelleri) Glucomannan as Anti-SARS-Cov-2. ELECTRON J GEN MED 2022;19:em340. [DOI: 10.29333/ejgm/11402] [Reference Citation Analysis]
|
| 6 |
Chawla U, Kashyap MK, Husain A. Aging and diabetes drive the COVID-19 forwards; unveiling nature and existing therapies for the treatment. Mol Cell Biochem 2021. [PMID: 34169437 DOI: 10.1007/s11010-021-04200-7] [Reference Citation Analysis]
|
| 7 |
Awadasseid A, Wu Y, Tanaka Y, Zhang W. Current advances in the development of SARS-CoV-2 vaccines. Int J Biol Sci 2021;17:8-19. [PMID: 33390829 DOI: 10.7150/ijbs.52569] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 18.0] [Reference Citation Analysis]
|
| 8 |
Chawla U, Kashyap MK, Husain A. Aging and diabetes drive the COVID-19 forwards; unveiling nature and existing therapies for the treatment. Mol Cell Biochem 2021;476:3911-22. [PMID: 34169437 DOI: 10.1007/s11010-021-04200-7] [Reference Citation Analysis]
|
| 9 |
Kebria MM, Milan PB, Peyravian N, Kiani J, Khatibi S, Mozafari M. Stem cell therapy for COVID-19 pneumonia. Mol Biomed 2022;3:6. [PMID: 35174448 DOI: 10.1186/s43556-021-00067-8] [Reference Citation Analysis]
|
| 10 |
Biberoğlu S, İpekci A, İkizceli İ, Çakmak F, Akdeniz YS, Kanbakan A, Konukoğlu D, Bolayırlı İM, Börekçi Ş, Ürkmez S, Özkan S. Role of plasma angiotensin II and angiotensin-converting enzyme 2 levels on prognosis and mortality in hypertensive patients with COVID-19. Biomark Med 2021;15:1581-8. [PMID: 34704822 DOI: 10.2217/bmm-2021-0121] [Reference Citation Analysis]
|
| 11 |
Baldeón ME, Maldonado A, Ochoa-Andrade M, Largo C, Pesantez M, Herdoiza M, Granja G, Bonifaz M, Espejo H, Mora F, Abril-López P, Armijo LKR, Pacheco V, Salazar R, Reinthaller S, Zertuche F, Fornasini M. Effect of convalescent plasma as complementary treatment in patients with moderate COVID-19 infection. Transfus Med 2022. [PMID: 35001439 DOI: 10.1111/tme.12851] [Reference Citation Analysis]
|
| 12 |
Mule S, Singh A, Greish K, Sahebkar A, Kesharwani P, Shukla R. Drug repurposing strategies and key challenges for COVID-19 management. J Drug Target 2021;:1-17. [PMID: 34854327 DOI: 10.1080/1061186X.2021.2013852] [Reference Citation Analysis]
|
| 13 |
Akbarzadeh-Khiavi M, Torabi M, Rahbarnia L, Safary A. Baricitinib combination therapy: a narrative review of repurposed Janus kinase inhibitor against severe SARS-CoV-2 infection. Infection 2021. [PMID: 34902115 DOI: 10.1007/s15010-021-01730-6] [Reference Citation Analysis]
|
| 14 |
Luo L, Qiu Q, Huang F, Liu K, Lan Y, Li X, Huang Y, Cui L, Luo H. Drug repurposing against coronavirus disease 2019 (COVID-19): A review. J Pharm Anal 2021. [PMID: 34513115 DOI: 10.1016/j.jpha.2021.09.001] [Reference Citation Analysis]
|
| 15 |
Mena-Vázquez N, Manrique Arija S, Rojas-Giménez M, Raya-Álvarez E, Velloso-Feijoó ML, López-Medina C, Ramos-Giraldez C, Godoy-Navarrete FJ, Redondo-Rodríguez R, Cabezas-Lucena AM, Morales-Águila M, Romero-Barco CM, Fernández-Nebro A. Hospitalization and Mortality from COVID-19 of Patients with Rheumatic Inflammatory Diseases in Andalusia. Reumatol Clin (Engl Ed) 2021:S1699-258X(21)00089-9. [PMID: 33895100 DOI: 10.1016/j.reuma.2021.02.009] [Reference Citation Analysis]
|
| 16 |
Zheng ZX. Stem cell therapy: A promising treatment for COVID-19. World J Clin Cases 2021; 9(36): 11148-11155 [DOI: 10.12998/wjcc.v9.i36.11148] [Reference Citation Analysis]
|
| 17 |
Tripp RA, Stambas J. Intervention Strategies for Seasonal and Emerging Respiratory Viruses with Drugs and Vaccines Targeting Viral Surface Glycoproteins. Viruses 2021;13:625. [PMID: 33917411 DOI: 10.3390/v13040625] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 18 |
Vlasov I, Panteleeva A, Usenko T, Nikolaev M, Izumchenko A, Gavrilova E, Shlyk I, Miroshnikova V, Shadrina M, Polushin Y, Pchelina S, Slonimsky P. Transcriptomic Profiles Reveal Downregulation of Low-Density Lipoprotein Particle Receptor Pathway Activity in Patients Surviving Severe COVID-19. Cells 2021;10:3495. [PMID: 34944005 DOI: 10.3390/cells10123495] [Reference Citation Analysis]
|
